Jinling Pharmaceutical Company Limited (000919) Company Profile


	The Wright Reports site is no longer hosted or operated by Manta. Please review the following: 1. You have been redirected to CorporateInformation.com where you can view Snapshot reports or purchase Wright reports or subscriptions of your choosing. 2. If you were previously linking to Wright Reports please change your links to www.corporateinformation.com 3. If you are a paid subscriber with an active subscription please continue on to the member site: http://member.corporateinformation.com/home.asp 4. For additional information related to CorporateInformation.com please contact help@corporateinformation.com, Contact phone nr to be provided later)

Jinling Pharmaceutical Company Limited Company Snapshot

Business Description:

Jinling Pharmaceutical Company Limited operates in the Diagnostic substances sector. Jinling Pharmaceutical Co., Ltd is principally engaged in the manufacture and sale of traditional Chinese and western medical materials, as well as the research, production, technical services and development of new medical products. The Company mainly provides Mailuoning series, buflomedil hydrochloride injections, Shuangxiang Paishi granules, ferrous succinate tablets, Weide'an capsules, lentinan injections, Sibai Quban gels, Jinluoring gels, Manyanning tablets and absorbable gelatin sponge, among others. The Company distributes its products mainly in domestic markets. As of December 31, 2010, the Company had 12 subsidiaries. In our complete report available for purchase the company is compared to: Shandong Lukang Pharmaceutical, Wuhan Humanwell Healthcare (Group) Company Limited and American Oriental Bioengineering, Incorporation.

Jinling Pharmaceutical Company Limited

Stock Data:

Recent Stock Performance:

Current Price (2/3/2012): 7.85
(Figures in Chinese Renmimbi)

1 Week	n/a	13 Weeks	7.5%

4 Weeks	-18.2%	52 Weeks	-21.1%

Jinling Pharmaceutical Company Limited Key Data:

Ticker:	000919	Country:	CHINA

Exchanges:	SZN	Major Industry:	Drugs, Cosmetics & Health Care

		Sub Industry:	Ethical Drug Manufacturers

2010 Sales	2,161,139,000 (Year Ending Jan 2011).	Employees:	3,388

Currency:	Chinese Renmimbi	Market Cap:	3,956,400,000

Fiscal Yr Ends:	December	Shares Outstanding:	504,000,000

Share Type:	A Gu	Closely Held Shares:	N/A

Feedback | Terms and Conditions | Privacy Policy | Site Index

CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.